Nanopills release drugs directly from the inside of cells

Mar 16, 2012

Universitat Autonoma de Barcelona researchers developed a new vehicle to release proteins with therapeutic effects. The vehicles are known as "bacteria inclusion bodies", stable insoluble nanoparticles which are found normally in recombinant bacteria. Even though these inclusion bodies traditionally have been an obstacle in the industrial production of soluble enzymes and biodrugs, they were recently recognised to have large amounts of functional proteins with direct values in industrial and biomedical applications.

The research team led by Antoni Villaverde from the Institute of Biotechnology and Biomedicine (IBB) at UAB worked in collaboration with the spanish Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) to verify the value of these as natural "nanopills" with a strong capacity to penetrate cells and carry out biological activities. The nanopill concept represents a new and promising platform for drug administration and illustrates the yet to be explored power of microbial materials in medicine.

The researchers, in a multidisciplinary study at UAB led by Dr Esther Vàzquez, packaged four proteins containing different therapeutic effects into experimental nanopills, the inclusion bodies of the bacteria Escherichia coli. They put the bacteria in contact with cell cultures of mammals under similar conditions to those found in real clinical pathologies, "sick" cells with low viability, and achieved to recover their activity.

Once the technology was licensed to Janus Developments, the tolerance of its administration in vivo was confirmed through experiments conducted by UAB researcher Ester Fernández. The results and detailed description of the "nanopill" were published in the last issue of the journal Advanced Materials.

The multidisciplinary study included researchers from IBB, the UAB Departments of Genetics and Microbiology and of Cell Biology, Physiology and Immunology, the CIBER-BBN, the CIBER-EHD (Centro de Investigación Biomédica en Red en el Área temática de Enfermedades hepáticas y Digestivas), the firm Janus Developments, the Leibniz University of Hannover and the Helmholtz Centre for Infection Research in Germany.

The use of inclusion bodies as therapeutic agents was patented by UAB and CIBER-BBN (patent code: WO2010131117A1), and licensed to the firm Janus Developments, which currently invests in the development of the product.

Explore further: Physicists create new nanoparticle for cancer therapy

Provided by Universitat Autonoma de Barcelona

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

New discoveries in cell aging

Jan 23, 2012

A group of researchers led by the Institute of Biotechnology and Biomedicine (IBB) and Universitat Autònoma de Barcelona (UAB) have achieved to quantify with precision the effect of protein aggregation on cell aging ...

Addiction index updated

Oct 27, 2010

The new version of the Addiction Severity Index (ASI) gives health professionals the opportunity to design an integral and personalised plan of assistance for patients suffering disorders due to substance ...

Freeing protein-based drugs from bacteria's natural traps

Oct 13, 2008

In a finding that could speed the development of new protein-based drugs for fighting diabetes, hepatitis, and other diseases, researchers are reporting progress toward preventing or destroying an unusual structure that reduces ...

Recommended for you

Physicists create new nanoparticle for cancer therapy

11 hours ago

A University of Texas at Arlington physicist working to create a luminescent nanoparticle to use in security-related radiation detection may have instead happened upon an advance in photodynamic cancer therapy.

User comments : 0

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.